Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.

@article{Kimball2008ClobetasolPE,
  title={Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.},
  author={Alexa B Kimball and Michael H Gold and Beth Zib and Mark W. Davis},
  journal={Journal of the American Academy of Dermatology},
  year={2008},
  volume={59 3},
  pages={448-54, 454.e1}
}
BACKGROUND Clobetasol propionate 0.05% emulsion foam was recently developed for use on multiple body sites. OBJECTIVE We sought to evaluate safety and efficacy of clobetasol emulsion foam 0.05% to treat steroid-responsive dermatoses in multiple age groups. METHODS A phase II open-label study evaluated the effect of clobetasol foam on the hypothalamic… CONTINUE READING